Polymeric CRISPR Delivery via Cationic Cargo Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vector-based delivery systems for CRISPR therapeutics face challenges such as high costs, lengthy manufacturing times, regulatory hurdles, limited cargo capacity, and safety concerns like carcinogenic mutations and systemic inflammatory responses, necessitating the development of synthetic polymer substitutes for safe, scalable, and affordable gene delivery.
Innovation Solution
Development of polymeric delivery systems, including polymers of formula (I) and (II), which form complexes with biological agents like nucleic acids and proteins, optimized through machine learning models to enhance delivery efficiency and safety, using post-polymerization modifications and cationic polymers to encapsulate and release genetic material within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If viral vectors are used for CRISPR delivery, then delivery capability is achieved, but manufacturing cost and time increase significantly
Solution Approach 1:
The patent uses synthetic polymers as copy substitutes for viral vectors. These polymers replicate the delivery function of viral vectors (transporting CRISPR cargo into cells) without requiring complex viral manufacturing processes, thereby reducing cost and time while maintaining delivery capability
Solution Approach 2:
The patent modifies polymer parameters (charge, hydrophobicity, molecular weight) to optimize delivery efficiency. By adjusting these parameters, the synthetic polymers achieve comparable or superior delivery performance to viral vectors while being much easier and faster to manufacture
2Quantity of substance
If viral vectors are used for CRISPR delivery, then gene delivery is achieved, but cargo capacity is limited
Solution Approach 1:
The patent employs composite polymer structures combining cationic moieties with hydrophobic and hydrophilic segments. This composite architecture enables the polymers to encapsulate and protect larger CRISPR cargoes (such as ribonucleoprotein complexes) while maintaining efficient cellular uptake and delivery
3Reliability
If viral vectors are used for CRISPR delivery, then therapeutic effect is achieved, but safety risks increase
Solution Approach 1:
The patent employs synthetic polymers that are non-infectious and do not integrate into the host genome, eliminating the safety risks associated with viral vectors (carcinogenic mutations, systemic inflammation). These polymers are designed to be biodegradable and non-immunogenic, providing a safer alternative that maintains therapeutic effectiveness
Solution Approach 2:
The patent converts the potential harm of viral vectors (immunogenicity, integration risks) into benefit by using synthetic polymers that deliberately avoid these problematic features. The polymers are designed to be chemically stable yet biodegradable, providing therapeutic effect without the harmful side effects of viral systems
4Reliability
If cationic polymers are used for delivery, then nucleic acid binding is achieved, but delivery efficiency is reduced
Solution Approach 1:
The patent introduces local quality variations through hydrophobic and hydrophilic segments within the polymer structure. The cationic moieties provide strong nucleic acid binding, while the hydrophobic segments facilitate cellular membrane interaction and endosomal escape, and hydrophilic segments ensure solubility and reduce toxicity, thereby improving overall delivery efficiency
Solution Approach 2:
The patent employs dynamic polymer-cargo interactions where the polymer structure can adapt its conformation based on environmental conditions (pH, ionic strength). This dynamic behavior allows the polymer to bind nucleic acids strongly under physiological conditions while releasing them efficiently in the cellular environment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymeric systems offer improved delivery efficiency, reduced immunogenicity, and cost-effectiveness, minimizing immune activation and cellular toxicity while effectively delivering CRISPR payloads for gene editing and expression.
Implementation Method 1
in aqueous physiological solutions, cationic polymers can spontaneously bind with negatively charged pDNA and form interpolyelectrolyte complexes
Data Source
AI summary
This invention relates generally to polymeric delivery systems. The present polymeric delivery systems may be complexed with biological agents, including nucleic acids, peptides, proteins, or small molecules, for delivery to cells. In particular, the present polymeric delivery systems may be used in gene editing.